MediMix aims to bring high value medical information to Belgian healthcare professionals via multiple channels. Our team covers congresses and symposia all over the world, particularly in the hematology domain. In collaboration with Belgian and international experts, we bring the newest data to Belgian physicians.
Dr Lucia Perez-Lamas, a haematologist at the Puerta de Hierro University Hospital in Madrid, Spain, presented real-world evidence on the use of momelotinib in myelofibrosis (MF) patients with anaemia.
Dr Adriano Salaroli, a haematologist at the Institut Jules Bordet in Brussels, provides an update on cytopenic myelofibrosis, emphasising the need for increased awareness regarding this specific subtype of myelofibrosis.
Dr Yana Stepanishyna, a haematologist at the Institut Jules Bordet in Brussels, presents a preliminary analysis from the SOPRALLO project.
Allogeneic hematopoietic stem cell transplantation (HSCT) has significantly extended the
Epcoritamab (EPCOR) is a novel, subcutaneous CD3xCD20 bispecific antibody (bsAb) that has demonstrated deep and durable responses with manageable safety in patients with R/R FL following at least two systemic
Wouter Sleeckx, a doctoral researcher at the University of Ghent, presented his research on the therapeutic potential of targeting the IL-4 signalling pathway in a subset of T-ALL patients. His
Cristina Borin, a doctoral researcher at the University of Ghent and the Cancer Research Institute Ghent (CRIG) presented her work on the functional characterization of Kdm6b in immature leukemia. Her
Dr Yvan Momo, a haematologist at the Hopital Universitaire de Bruxelles in Brussels, presents an analysis of transfusion practices in a Belgian sickle cell reference centre, assessing their adherence to
The current standard treatment for R/R cHL involves salvage chemotherapy followed by ASCT. However, the optimal salvage therapy regimen remains undefined. Recent evidence suggests that the combination of brentuximab vedotin
